Total Payments
$207,556
2024 Payments
$18,112
Companies
18
Transactions
348
Medicare Patients
3,331
Medicare Billing
$913,407
Payment Breakdown by Category
Other$192,379 (92.7%)
Food & Beverage$8,950 (4.3%)
Travel$6,026 (2.9%)
Education$201.01 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $192,379 | 142 | 92.7% |
| Food and Beverage | $8,950 | 139 | 4.3% |
| Travel and Lodging | $6,026 | 62 | 2.9% |
| Education | $201.01 | 5 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $198,544 | 295 | $0 (2024) |
| Mallinckrodt LLC | $6,641 | 5 | $0 (2017) |
| AstraZeneca Pharmaceuticals LP | $405.06 | 5 | $0 (2024) |
| GlaxoSmithKline, LLC. | $348.26 | 3 | $0 (2024) |
| Lilly USA, LLC | $298.31 | 4 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $276.55 | 9 | $0 (2024) |
| UCB, Inc. | $224.04 | 3 | $0 (2024) |
| PFIZER INC. | $207.55 | 10 | $0 (2019) |
| Janssen Biotech, Inc. | $153.99 | 2 | $0 (2024) |
| AbbVie Inc. | $148.39 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $18,112 | 32 | Amgen Inc. ($17,625) |
| 2023 | $2,660 | 9 | Amgen Inc. ($2,398) |
| 2022 | $10,600 | 19 | Amgen Inc. ($10,165) |
| 2021 | $14,842 | 27 | Amgen Inc. ($14,420) |
| 2020 | $11,751 | 19 | Amgen Inc. ($11,659) |
| 2019 | $51,748 | 80 | Amgen Inc. ($51,423) |
| 2018 | $40,810 | 77 | Amgen Inc. ($40,584) |
| 2017 | $57,032 | 85 | Amgen Inc. ($50,270) |
All Payment Transactions
348 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| Category: Inflammation | ||||||
| 12/17/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $400.00 | General |
| Category: Inflammation | ||||||
| 12/17/2024 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | Cash or cash equivalent | $170.18 | General |
| Category: Inflammation | ||||||
| 12/12/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $87.42 | General |
| Category: Inflammation | ||||||
| 12/03/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $124.74 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $300.00 | General |
| Category: Inflammation | ||||||
| 11/07/2024 | UCB, Inc. | Bimzelx (Biological) | Food and Beverage | In-kind items and services | $73.18 | General |
| Category: Immunology | ||||||
| 09/30/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| Category: Inflammation | ||||||
| 09/30/2024 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | Cash or cash equivalent | $31.49 | General |
| Category: Inflammation | ||||||
| 09/28/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $38.65 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 09/25/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $65.10 | General |
| Category: Inflammation | ||||||
| 08/22/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $400.00 | General |
| Category: Inflammation | ||||||
| 07/10/2024 | AstraZeneca Pharmaceuticals LP | SAPHNELO (Biological) | Food and Beverage | In-kind items and services | $81.53 | General |
| Category: Inflammation and Autoimmunity | ||||||
| 05/16/2024 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | Cash or cash equivalent | $53.60 | General |
| Category: Inflammation | ||||||
| 05/14/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| Category: Inflammation | ||||||
| 05/14/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $400.00 | General |
| Category: Inflammation | ||||||
| 05/09/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $75.76 | General |
| Category: Inflammation | ||||||
| 05/08/2024 | UCB, Inc. | Cimzia (Drug) | Food and Beverage | In-kind items and services | $67.10 | General |
| Category: Immunology | ||||||
| 04/24/2024 | Amgen Inc. | Otezla (Drug) | Travel and Lodging | Cash or cash equivalent | $131.99 | General |
| Category: Inflammation | ||||||
| 04/23/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| Category: Inflammation | ||||||
| 04/23/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $400.00 | General |
| Category: Inflammation | ||||||
| 04/18/2024 | Amgen Inc. | Otezla (Drug) | Food and Beverage | In-kind items and services | $111.94 | General |
| Category: Inflammation | ||||||
| 04/03/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Education | In-kind items and services | $54.99 | General |
| Category: Immunology | ||||||
| 03/26/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,400.00 | General |
| Category: Inflammation | ||||||
| 03/26/2024 | Amgen Inc. | Otezla (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $400.00 | General |
| Category: Inflammation | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 916 | 10,976 | $547,548 | $259,257 |
| 2022 | 10 | 870 | 11,073 | $472,616 | $244,097 |
| 2021 | 11 | 857 | 11,155 | $409,518 | $240,741 |
| 2020 | 9 | 688 | 8,420 | $312,944 | $169,312 |
Total Patients
3,331
Total Services
41,624
Medicare Billing
$913,407
Procedure Codes
40
All Medicare Procedures & Services
40 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 97 | 9,900 | $366,300 | $181,531 | 49.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 346 | 487 | $90,715 | $42,077 | 46.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 122 | 122 | $34,950 | $13,780 | 39.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 115 | 122 | $15,236 | $7,453 | 48.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 50 | 54 | $13,506 | $6,999 | 51.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 117 | 196 | $9,421 | $2,129 | 22.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 15 | 15 | $5,515 | $2,048 | 37.1% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 23 | 23 | $4,505 | $1,637 | 36.3% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 16 | 27 | $6,992 | $1,438 | 20.6% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2023 | 15 | 30 | $408.00 | $163.57 | 40.1% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 101 | 10,080 | $302,760 | $170,182 | 56.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 374 | 502 | $93,016 | $42,964 | 46.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 91 | 91 | $26,071 | $10,459 | 40.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 50 | 57 | $14,225 | $7,288 | 51.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 66 | 67 | $8,141 | $4,461 | 54.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 28 | 28 | $10,252 | $4,246 | 41.4% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 108 | 181 | $8,686 | $1,993 | 22.9% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2022 | 22 | 29 | $6,400 | $1,584 | 24.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 14 | 14 | $2,740 | $795.05 | 29.0% |
| J1030 | Injection, methylprednisolone acetate, 40 mg | Office | 2022 | 16 | 24 | $325.00 | $125.81 | 38.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 97 | 10,140 | $243,360 | $164,858 | 67.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 352 | 493 | $89,556 | $43,473 | 48.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 109 | 109 | $30,649 | $13,407 | 43.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 43 | 47 | $11,597 | $6,161 | 53.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 57 | 63 | $7,557 | $4,323 | 57.2% |
About Dr. Mark Diehl, DO
Dr. Mark Diehl, DO is a Internal Medicine healthcare provider based in Gettysburg, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1982667754.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Diehl, DO has received a total of $207,556 in payments from pharmaceutical and medical device companies, with $18,112 received in 2024. These payments were reported across 348 transactions from 18 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($192,379).
As a Medicare-enrolled provider, Diehl has provided services to 3,331 Medicare beneficiaries, totaling 41,624 services with total Medicare billing of $913,407. Data is available for 4 years (2020–2023), covering 40 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Rheumatology
- Location Gettysburg, PA
- Active Since 04/11/2006
- Last Updated 06/13/2016
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1982667754
Products in Payments
- Enbrel (Biological) $92,873
- Prolia (Biological) $56,881
- Otezla (Drug) $18,831
- EVENITY (Biological) $11,731
- ACTHAR (Biological) $6,641
- SAPHNELO (Biological) $405.06
- BENLYSTA (Biological) $348.26
- COSENTYX (Biological) $217.43
- XELJANZ (Drug) $207.55
- TALTZ (Drug) $157.08
- TREMFYA (Drug) $153.99
- SIMPONI ARIA (Biological) $124.99
- RINVOQ (Biological) $75.93
- OLUMIANT (Drug) $75.19
- LUPKYNIS (Drug) $73.22
- Bimzelx (Biological) $73.18
- Cimzia (Drug) $67.10
- COSENTYX (Drug) $59.12
- Tavneos (Drug) $57.62
- Truvada (Drug) $21.12
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Gettysburg
Dr. Muhammad Saad, M.d, M.D
Internal Medicine — Payments: $6,552
Internal Medicine $6,552
Graham Foose, Do, DO
Internal Medicine — Payments: $3,655
Internal Medicine $3,655
Dr. John Kalloz, Md, MD
Internal Medicine — Payments: $2,502
Internal Medicine $2,502
Rajwinder Kaur, M.d, M.D
Internal Medicine — Payments: $2,339
Internal Medicine $2,339
Stephanie Kekulawela, M.d, M.D
Internal Medicine — Payments: $2,285
Internal Medicine $2,285
Mr. Simon Mathews, Md, MD
Internal Medicine — Payments: $2,250
Internal Medicine $2,250